Amneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2025 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.650-0.70 for the period, compared to the consensus estimate of 0.680. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion.

Amneal Pharmaceuticals Stock Up 3.0 %

NASDAQ AMRX opened at $7.97 on Friday. The firm has a market cap of $2.47 billion, a PE ratio of -11.72 and a beta of 1.17. Amneal Pharmaceuticals has a 52 week low of $6.29 and a 52 week high of $9.48. The company has a 50 day moving average price of $8.02 and a 200 day moving average price of $8.16.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, May 2nd. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The firm had revenue of $695.42 million during the quarter, compared to analysts’ expectations of $714.78 million. On average, equities research analysts anticipate that Amneal Pharmaceuticals will post 0.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AMRX has been the subject of a number of research analyst reports. Barclays raised their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, March 3rd. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Amneal Pharmaceuticals has a consensus rating of “Buy” and an average target price of $10.80.

Insider Transactions at Amneal Pharmaceuticals

In other news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now directly owns 48,578,209 shares of the company’s stock, valued at $405,628,045.15. This represents a 9.33 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gautam Patel sold 80,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $8.14, for a total value of $651,200.00. Following the sale, the director now owns 1,888,886 shares in the company, valued at $15,375,532.04. This trade represents a 4.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,160,000 shares of company stock worth $43,113,200 over the last quarter. 26.56% of the stock is currently owned by insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.